In this study, hydroxyapatite (HA) was extracted from biological waste. HA was modified by N,N-diglycidylaniline (NDY) and DOPO-HQ to obtain the flame retardant which was added to epoxy resin (EP) to prepare the composite. The flame retardancy of the composites was measured by the horizontal and vertical combustion tester (UL-94) and the limiting oxygen index (LOI), the thermal property was carried out by the thermogravimetric analyzer (TGA), and the surface morphology was observed by the field emission scanning electron microscope (SEM). The UL-94 grade of pure EP is a fail grade, and the LOI value was 22%. After adding HA-NDY-DOPOHQ (weight ratio 1:2:1) 40[Formula: see text]wt.% flame retardant, the UL-94 grade of the composites was raised to V-1, and the LOI value promoted to 28%, a total increase of 6%. Composite materials had excellent thermal stability and flame retardancy and could be used in fireproof panels for energy storage systems to prevent thermal runaway, and could also be used in building materials.

2024-10-01·European Journal of Trauma and Emergency Surgery

Shock index to predict outcomes in patients with trauma following traffic collisions: a retrospective cohort study

Article

作者: Liao, Te-Kai ; Cheng, Li-Chin ; Ho, Chung-Han ; Lin, Ying-Jia ; Huang, Hsuan-Yi

Abstract:

Purpose:

Taiwan, which has a rate of high vehicle ownership, faces significant challenges in managing trauma caused by traffic collisions. In Taiwan, traffic collisions contribute significantly to morbidity and mortality, with a high incidence of severe bleeding trauma. The shock index (SI) and the modified shock index (MSI) have been proposed as early indicators of hemodynamic instability. In this study, we aimed to assess the efficacy of SI and MSI in predicting adverse outcomes in patients with trauma following traffic collisions.

Methods:

This retrospective cohort study was conducted at Chi Mei Hospital from January 2015 to December 2020. The comprehensive analysis included 662 patients, with data collected on vital signs and outcomes such as mortality, blood transfusion, emergent surgical intervention (ESI), transarterial embolization (TAE), and intensive care unit (ICU) admission. Optimal cutoff points for SI and MSI were identified by calculating the Youden index. Logistic regression analysis was used to assess outcomes, adjusting for demographic and injury severity variables.

Results:

An SI threshold of 1.11 was associated with an increased risk of mortality, while an SI of 0.84 predicted the need for blood transfusion in the context of traffic collisions. Both SI and MSI demonstrated high predictive power for mortality and blood transfusion, with acceptable accuracy for TAE, ESI, and ICU admission. Logistic regression analyses confirmed the independence of SI and MSI as risk factors for adverse outcomes, thus, providing valuable insights into their clinical utility.

Conclusions:

SI and MSI are valuable tools for predicting mortality and blood transfusion needs in patients with trauma due to traffic collisions. These findings advance the quality of care for patients with trauma during their transition from the emergency room to the ICU, facilitating prompt and reliable decision-making processes and improving the care of patients with trauma.

2024-08-01·IEEE SENSORS JOURNAL

Enhanced pH Sensing Capability by Platinum Adsorption Onto Titanium Dioxide Nanorods

作者: Chen, De-Qian ; Su, Li-Yun ; Yang, Chih-Chiang ; Huang, Chien-Sheng

Titanium dioxide (TiO2) and Pt/TiO2 nanorods are fabricated on fluorine-doped tin oxide (FTO) glass substrates using hydrothermal methods and sputter coating.These materials serve as the sensing films for pH sensors that operate based on an extended-gate field-effect transistor (EGFET).The sensors measure the p.d. between the sensing film and an Ag/AgCl reference electrode across various pH buffer solutionsThe IDS-VG curves indicate that the reference voltage (Vref) increases with pH.The voltage sensitivity and linearity, determined through linear fitting with the IDS fixed at 1 mA, are 28.5 mV/pH and 0.947 for TiO2 nanorods, resp.These values increase to 50 mV/pH and 0.991 with the addition of Pt on TiO2.Current sensitivity, a crucial metric for sensor quality, is evaluated in the saturation region (IDS-VDS curves) at a fixed saturation voltage of 3 V.As pH increases, IDS decreases, with current sensitivity for TiO2 nanorods at 38.3 μA/pH and linearity at 0.921.This sensitivity enhances to 63.8 μA/pH with the linearity of 0.988 when Pt is added to TiO2.Hysteresis and stability tests demonstrate that Pt/TiO2 nanorods maintain a broad sensing range (pH 3-11) and exhibit superior stability.The increased sensitivity of the EGFET with Pt/TiO2 coating compared to TiO2 can be attributed to higher surface site d., improved ion detection, enhanced conductivity, better carrier transport, and greater surface roughness, all of which enhance reactivity and boost voltage and current sensitivities.Consequently, Pt/TiO2 nanorods are exceptionally suitable for biomedical applications and pH sensing.

项与南台科技大学相关的新闻（医药）

2024-06-07

·PRNewswire

MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New Era Multi-Target Drug for the Treatment of Alzheimer's Disease

TAINAN, June 7, 2024 /PRNewswire/ -- MLB (Merry Life Biomedical Company, Ltd., Taiwan: ), a biomedical company, announced that the U.S. Food and Drug Administration (FDA) has approved IND application for TML-6, an novel drug to treat Alzheimer's disease (AD), enabling a Phase 1 clinical trial to be initiated this July. Advancing TML-6 into clinical trial is a critical milestone for MLB to develop a new era multi-target drug for AD since 2018. About TML-6 Continue Reading TML-6 is a novel synthetic curcumin analog. Professor Ih-Jen Su at Southern Taiwan University used a platform of 6 aging and AD biomarkers to screen the 12 compounds from Androscience (San Diego, USA) for AD candidate. Preclinical studies showed that TML-6 (ASC-6) exhibits a multi-target action mechanism for AD, including anti-aging, activation of autophagy (mTOR inhibitor), reducing amyloid accumulation, and anti-inflammation (Figure 1), the efficacy confirmed by 2 AD animal models. TML-6 has a high bioavailability through formulation and then completed preclinical toxicology and safety studies. TML-6 should be potentially a novel drug to improve or reverse the progression of early-stage AD. The Design and Future Plan of TML-6 for AD Clinical Trial s TML-6 is developed as an oral drug and will conduct a SAD/MAD phase 1 clinical trial at Glendale Adventist Medical Center, LA, USA in 2024 Q3. Elderly cohort and CSF pharmacokinetics (PK) studies were specifically designed. For a global multi-site phase 2a clinical trial, several distinguished global AD experts provided consultation. Blood biomarkers will be included in the phase 2a trial as the surrogate endpoint of efficacy. Furthermore, TML-6 is considering to combine with the current anti-amyloid drugs in phase 2 trial. The drug combination could not only exhibit synergistic effects to improve AD behavior, reducing amyloid accumulation and ant-inflammation, but can also reduce antibody dosing to only 10% and avoid the adverse events (ARIAs) of anti-body drugs. MLB has successfully raised funds to conduct this global phase 2a clinical trial, scheduled to be conducted on 2025 Q3. Contact: Chien Hong Lin, PhD Email: [email protected] SOURCE Merry Life Biomedical Company, Ltd.